Portopulmonary hypertension and hepatorenal syndrome. Two faces of the same coin


      • Genetic predisposition and venovenous shunt favor the portopulmonary hypertension.
      • Hepatorenal reflex and sympathetic nervous system favor the hepatorenal syndrome.
      • Portopulmonary hypertension has a satisfactory prognosis after liver transplant.
      • Hepatorenal syndrome type1 has a worse prognosis than type 2.


      Portopulmonary hypertension and hepatorenal syndrome are both severe local hypertensive complications of liver cirrhosis and portal hypertension. Both are characterized by vasoconstrictive manifestations regarding pulmonary and renal vascular network, respectively.
      This review addresses the mechanisms underlying the development of vasoconstriction that leads to local vascular hypertension in the lung and in the kidney with the result of organ dysfunction. Potential therapeutic options are available for the management of these two syndromes as a bridge for liver transplantation; clinical efficacy depends in part on the time and rapidity of intervention and in part on how serious the chain of events is that has triggered the entire vasoconstrictive process.


      HRS (hepatorenal syndrome), HVPG (hepatic venous pressure gradient), PPH (portopulmonary hypertension)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zardi E.M.
        • Dobrina A.
        • Ambrosino G.
        • et al.
        New therapeutic approaches to liver fibrosis: a practicable route?.
        Curr. Med. Chem. 2008; 15: 1628-1644
        • Zardi E.M.
        • Navarini L.
        • Sambataro G.
        • et al.
        Hepatic PPARs: their role in liver physiology, fibrosis and treatment.
        Curr. Med. Chem. 2013; 20: 3370-3396
        • Zardi E.M.
        • Di Matteo F.M.
        • Pacella C.M.
        • et al.
        Invasive and non-invasive techniques for detecting portal hypertension and predicting variceal bleeding in cirrhosis: a review.
        Ann. Med. 2014; 46: 8-17
        • Møller S.
        • Bendtsen F.
        Cirrhotic multiorgan syndrome.
        Dig. Dis. Sci. 2015; 60: 3209-3225
        • Krowka M.J.
        • Swanson K.L.
        • Frantz R.P.
        • et al.
        Portopulmonary hypertension: results from a 10-year screening algorithm.
        Hepatology. 2006; 44: 1502-1510
        • Talwaker J.A.
        • Swanson K.L.
        • Krowka M.J.
        • et al.
        Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment.
        Gastroenterology. 2011; 141: 1673-1679
        • Zardi E.M.
        • Uwechie V.
        • Caccavo D.
        • et al.
        Portosystemic shunts in a large cohort of patients with liver cirrhosis: detection rate and clinical relevance.
        J. Gastroenterol. 2009; 44: 76-83
        • Henriksen J.H.
        • Ring-Larsen H.
        Hepatorenal disorders: role of the sympathetic nervous system.
        Semin. Liver Dis. 1994; 14: 35-43
        • Schrier R.W.
        • Arroyo V.
        • Bernardi M.
        • et al.
        Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
        Hepatology. 1988; 8: 1151-1157
        • Francoz C.
        • Nadim M.K.
        • Durand F.
        Kidney biomarkers in cirrhosis.
        J. Hepatol. 2016; 65: 809-824
        • Mantz Jr., F.A.
        • Craige E.
        Portal axis thrombosis with spontaneous portacaval shunt and resistant cor pulmonale.
        AMA Arch Pathol. 1951; 52: 401-409
        • Krowka M.J.
        • Mandell S.M.
        • Ramsay M.A.
        • et al.
        Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database.
        Liver Transpl. 2004; 10: 174-182
        • Torregrosa M.
        • Genesca J.
        • Evangelista A.
        • et al.
        Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates.
        Transplantation. 2001; 71: 572-574
        • Cosarderelioglu C.
        • Cosar A.M.
        • Gurakar M.
        • et al.
        Portopulmonary hypertension and liver transplant: recent review of the literature.
        Exp. Clin. Transplant. 2016; 14: 113-120
        • Krowka M.J.
        • Plevak D.J.
        • Findlay J.Y.
        • et al.
        Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation.
        Liver Transpl. 2000; 6: 443-450
        • Lv Y.
        • Han G.
        • Fan D.
        Portopulmonary hypertension.
        Scand. J. Gastroenterol. 2016; 51: 795-806
        • Goldberg D.S.
        • Batra S.
        • Sahay S.
        • et al.
        MELD exceptions for Portopulmonary hypertension: current policy and future implementation.
        Am. J. Transplant. 2014; 14: 2081-2087
        • Zardi E.M.
        • Picardi A.
        • Ambrosino G.
        • et al.
        Hemodynamic effects of a prostacyclin analog (iloprost) on portal flow velocity and volume and visceral artery circulation in patients with lower limb arteriopathy.
        Ultrasound Med. Biol. 2003; 29: 209-213
        • Sakai T.
        • Planinsic R.M.
        • Mathier M.A.
        • et al.
        Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease.
        Transpl. Int. 2009; 22: 554-561
        • Austin M.J.
        • McDougall N.I.
        • Wendon J.A.
        • et al.
        Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension.
        Liver Transpl. 2008; 14: 287-291
        • Savale L.
        • Magnier R.
        • Le Pavec J.
        • et al.
        Efficacy, safety, and pharmacokinetics of bosentan in portopulmonary hypertension.
        Eur. Respir. J. 2013; 41: 96-103
        • Raevens S.
        • De Pauw M.
        • Reyntjens K.
        • et al.
        Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation.
        Eur. J. Gastroenterol. Hepatol. 2013; 25: 495-502
        • Bozbas S.S.
        • Bozbas H.
        Portopulmonary hypertension in liver transplant candidates.
        World J. Gastroenterol. 2016; 22: 2024-2029
        • Carvalho G.C.
        • Regis Cde A.
        • Kalil J.R.
        • et al.
        Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality.
        Ann. Hepatol. 2012; 11: 90-95
        • Dundar H.Z.
        • Yilmazlar T.
        Management of hepatorenal syndrome.
        World J Nephrol. 2015; 4: 277-286
        • Koppel M.H.
        • Coburn J.W.
        • Mims M.M.
        • et al.
        Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease.
        N. Engl. J. Med. 1969; 280: 1367-1371
        • Mohanty A.
        • Garcia Tsao G.
        Hyponatremia and hepatorenal syndrome.
        Gastroenterol. Hepatol. 2015; 11: 220-229
        • Zhang Q.
        • Guo X.
        • Zhao S.
        • et al.
        Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: a study of 164 patients.
        Exp Ther Med. 2016; 11: 1348-1354
        • Appenrodt B.
        • Zielinski J.
        • Brensing K.A.
        • et al.
        Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis.
        Eur. J. Gastroenterol. Hepatol. 2009; 21: 1428-1432
        • Salerno F.
        • Cazzaniga M.
        • Merli M.
        • et al.
        Italian Association of the Hospital Gastroenterologists (AIGO) investigators. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice.
        J. Hepatol. 2011; 55: 1241-1248
        • Okamura Y.
        • Hata K.
        • Inamoto O.
        • et al.
        Influence of Hepatorenal syndrome on outcome of living donor liver transplantation: a single-center experience in 357 patients.
        Hepatol. Res. 2016;
        • Sanyal A.J.
        • Boyer T.
        • Garcia-Tsao G.
        • Terlipressin Study Group
        • et al.
        A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.
        Gastroenterology. 2008; 134: 1360-1368
        • Salerno F.
        • Navickis R.J.
        • Wilkes M.M.
        Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis.
        BMC Gastroenterol. 2015; 15: 167
        • Cavallin M.
        • Kamath P.S.
        • Merli M.
        • et al.
        Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
        Hepatology. 2015; 62: 567-574
        • Singh V.
        • Ghosh S.
        • Singh B.
        • et al.
        Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.
        J. Hepatol. 2012; 56: 1293-1298
        • Cavallin M.
        • Fasolato S.
        • Marenco S.
        • et al.
        The treatment of Hepatorenal syndrome.
        Dig. Dis. 2015; 33: 548-554
        • Cárdenas A.
        • Ginès P.
        • Marotta P.
        • et al.
        Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
        J. Hepatol. 2012; 56: 571-578
        • Sinha V.K.
        • Ko B.
        Hyponatremia in cirrhosis--pathogenesis, treatment, and prognostic significance.
        Adv. Chronic Kidney Dis. 2015; 22: 361-367
        • Patidar K.R.
        • Sydnor M.
        • Sanyal A.J.
        Transjugular intrahepatic portosystemic shunt.
        Clin Liver Dis. 2014; 18: 853-876
        • Banares R.
        • Nevens F.
        • Larsen F.
        • et al.
        Extracorporeal albumin dialysis with the molecular adsorbend recirculating system in acute-on-chronic liver failure. The RELIEF trial.
        Hepatology. 2013; 57: 1153-1162